Advances in Pre-Epigenetically Reprogrammed Hyperactive Extracellular Vesicles for Major Diseases
1. Zhongke Bio-Manufacturing Innovation Center, Beijing 100407, China
2. Zhongke Jianlan Medical Research Institute, Beijing 100407, China
3. Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
| Abstract: | Human umbilical cord mesenchymal stem cell (hUC-MSC)-derived small extracellular vesicles (sEVs) serve as core cell-free regenerative therapeutics, featuring low immunogenicity, multi-barrier penetrability, multi-pathway synergistic regulation, and superior administration safety, which deliver innovative intervention strategies for refractory inflammatory, degenerative and neurodevelopmental disorders. Native unmodified sEVs are restricted by critical translational bottlenecks, including non-directional enrichment of bioactive cargos, excessive residual impurities post-isolation, poor compatibility across diverse administration routes, and the absence of full-chain quality control frameworks. An interdisciplinary research team co-established by the Institute of Biophysics, Chinese Academy of Sciences, Zhongke Bio-Manufacturing Innovation Center and Zhongke Jianlan Medical Research Institute developed an original integrated technical platform combining pre-epigenetic reprogramming directional modification and four-stage gradient GMP modular purification. By regulating epigenetic signals of the ESCRT sorting cascade, the system remodels the cargo spectrum of vesicular proteins, cytokines and regulatory non-coding RNAs, enabling directional production of three functional sEV subtypes: mucosal anti-inflammatory repair subtype, systemic immunomodulatory subtype, and soft tissue & cartilage regeneration subtype. Meanwhile, a GLP-standardized full-dimensional testing system matching seven clinical delivery routes (nebulized inhalation, intranasal delivery, ophthalmic administration, intravenous infusion, intra-articular injection, local lesion delivery, subcutaneous injection) was constructed. This review systematically elaborates the preparation principle, multi-dimensional physicochemical characterization and full-chain CMC quality specifications of engineered hyperactive sEVs, dissects molecular intervention mechanisms in five categories of severe refractory diseases including critical pulmonary injury, autism spectrum disorder, neurodegenerative diseases, osteoarthritis and systemic autoimmune disorders, and validates in vivo safety and therapeutic efficacy via real-world clinical cohort data. We comprehensively analyze current technical barriers restricting industrialization and clinical translation of engineered sEVs, and propose iterative research strategies including targeted membrane modification, multi-center large-sample randomized controlled clinical trials, and standardized full-industry-chain construction, providing systematic theoretical support and practical basis for standardized development of extracellular vesicle therapeutics, preclinical pharmacology & toxicology evaluation, and regulatory registration transformation. |
| Keywords: | Pre-epigenetic Reprogramming; Human Umbilical Cord Mesenchymal Stem Cells; Small Extracellular Vesicles; Cell-free Therapy; Major Refractory Diseases; Regenerative Medicine; Standardized Quality Control |
| DOI: | 10.57237/j.mrf.2026.04.001 |
View:
Downloads:
Received: 23 August 2026
Accepted: 20 September 2026
Published Online: 8 October 2026
References
| [1] | Welsh JA, et al. Minimal information for studies of extracellular vesicles 2023 (MISEV2023). Journal of Extracellular Vesicles, 2024, 13(1): e12433. |
| [2] | Chen J, et al. Human umbilical cord mesenchymal stromal cell small extracellular vesicle transfer of microRNA-223-3p attenuates inflammation in acute lung injury in mice. Journal of Nanobiotechnology, 2025, 23(1): 219. |
| [3] | Bertolino GM, Maumus M, Jorgensen C, et al. Therapeutic potential in rheumatic diseases of extracellular vesicles derived from mesenchymal stromal cells. Nature Reviews Rheumatology, 2023, 19(9): 547–564. |
| [4] | Zhang Y, et al. Extracellular vesicles for Alzheimer’s disease therapy: mechanisms, engineering strategies, and clinical translation. Advanced Science, 2026, 13(12): e2504128. |
| [5] | Liu Y, et al. Preconditioned mesenchymal stem cell-derived small extracellular vesicles: epigenetic cargo reprogramming and translational advances. Acta Biomaterialia, 2024, 172: 289–306. |
| [6] | Wang Z, et al. Engineered mesenchymal stem cell sEVs mitigate organ fibrosis via macrophage phenotype reprogramming. Biomaterials, 2026, 401: 122441. |
| [7] | Pham TT, et al. Nasal delivery of mesenchymal stem cell extracellular vesicles rescues neuroinflammation and autistic-like behaviors via TLR4/NF-κB inhibition. Brain, Behavior, and Immunity, 2025, 132: 418–432. |
| [8] | Zhang X, et al. Engineered MSC-sEVs for cartilage regeneration in osteoarthritis: multi-target matrix protection and synovial immunomodulation. Biomaterials Research, 2024, 28(1): 65. |
| [9] | Valadi H, et al. Cell-free therapeutics based on engineered small extracellular vesicles: industrial standardization and clinical regulatory challenges. Nature Reviews Drug Discovery, 2025, 24(3): 217–236. |
| [10] | Yan Z, et al. Epigenetic reprogramming amplifies therapeutic miRNA loading within mesenchymal stem cell small extracellular vesicles. Advanced Functional Materials, 2024, 34(28): e24018967. |
| [11] | Escudier B, et al. Extracellular vesicles as human therapeutics: systematic scoping review of clinical trial data. Journal of Extracellular Vesicles, 2024, 13(1): e12433. |
| [12] | Sun Y, et al. Mesenchymal stem cell-derived extracellular vesicles modulate Treg/Th17 balance to restore systemic immune tolerance in autoimmune disorders. Cellular & Molecular Immunology, 2025, 22(4): 678–694. |
| [13] | Valadi H, et al. Cell-free therapeutics based on engineered small extracellular vesicles: industrial standardization and clinical regulatory challenges. Nature Reviews Drug Discovery, 2025, 24(3): 217–236. |
| [14] | Ma Y, Dong S, Grippin A, et al. Engineering therapeutical extracellular vesicles for clinical translation. Trends in Biotechnology, 2025, 43(1): 61–82. |
| [15] | Louro AF, Meliciano A, Alves PM, et al. A roadmap towards manufacturing extracellular vesicles for cardiac repair. Trends in Biotechnology, 2024, 42(10): 1305–1322. |
Join the Editorial Board
We invite active, qualified and high profile scientists and researchers to join as Editorial Board Members.
Join UsBecome a Reviewer
Scholars with a strong interest in reviewing are invited to join the reviewer panel to ensure the quality of the research to be published.
Join Us